• Mashup Score: 4

    Left ventricular assist devices (LVAD) can be used as either short-term (ie, bridge) or long-term (ie, destination) therapies. In the latter instance, discussion with the patient about end of life with an LVAD is necessary. Important issues at end of life for these patients range from aggressive symptom management to quality-of-life and ethical dilemmas. Multiple members of the multidisciplinary…

    Tweet Tweets with this article
    • Perioperative Mechanical Circulatory Support Symposium / End-of-Life Issues in Patients With Left Ventricular Assist Devices | Mary Acelle G. Garcia, @AstridGrouls @MDAndersonNews @BCM_GeriPalli | #THIJournal https://t.co/LYfVFVcfL0 https://t.co/VgpEE3Wbw2

  • Mashup Score: 0

    In 2021, The Texas Heart Institute Board of Trustees created the James T. Willerson, MD, Editor’s Choice Award to honor his standards for excellence in research and scientific publishing. That year, 3 groups of authors whose articles were published in The Texas Heart Institute Journal received an award.Going forward, 2 primary authors will be recognized annually for their work on a Clinical…

    Tweet Tweets with this article
    • The James T. Willerson, MD, Editor's Choice Award | Zvonimir Krajcer, MD @Texas_Heart | #THIJournal https://t.co/ZOjjXafKro https://t.co/6QowDcmcXS

  • Mashup Score: 0

    On February 10, 2023, Dr Michael Nihill passed away peacefully at the age of 87 years. Those who were lucky enough to know him knew he was truly one of a kind.Born in 1936 in Haberfield, Australia, Dr Nihill completed his medical degree, internship, and pediatric residency in Sydney and then traveled to London, England, to work as a postgraduate student in internal medicine. Reflecting on this…

    Tweet Tweets with this article
    • In Memoriam: Michael R. Nihill, MBBS (1936–2023) | @drwaynefranklin Colin J. McMahon @danieljpenny of @PhxChildrens @CHI_Ireland @TexasChildrens | #THIJournal https://t.co/omvzeAr4BK https://t.co/exbkkEUVbA

  • Mashup Score: 0

    Context.—Providing blood products for transfusions is a complex process subject to errors both within and outside the transfusion service. Transfusion-related errors can have grave consequences for the patient undergoing transfusion. As with many processes performed within health care systems, there is an expectation of error-free practice. Although this is an unobtainable goal, a focused…

    Tweet Tweets with this article
    • Quality is no longer perceived as policing but champions of process improvement with the optimal role of ensuring patient safety. To learn more about this topic, check out these resources: 📑Start with this article 👉🏽Managing Transfusion Service Quality https://t.co/x4MLmulqlV

  • Mashup Score: 1

    When selecting conduits for coronary artery bypass, long-term patency, survival benefit, and patient factors such as coronary atherosclerotic burden and comorbid conditions are the primary influences on surgical decision-making (Fig. 1). Previous studies have shown that multiple arterial conduits offer a survival benefit,1 but the observational design of this work makes the findings subject to…

    Tweet Tweets with this article
    • Global CV Forum / Arterial Grafts in Coronary Artery Bypass Surgery: Who, When, and Why | N Roa-Vidal @LaurenBarronMD @medupr @Texas_Heart @bcmhouston | #THIJournal https://t.co/OVnANas3Md https://t.co/2C5tzk6rWz

  • Mashup Score: 1

    Albert Einstein once said, “The distinction between the past, present and future is only a stubbornly persistent illusion.”So much of what is done with complex aortic surgical interventions is a direct outgrowth of what has been done, what is being done, and what is intended to be accomplished.The first successful aortic aneurysm repair was performed by Dr Charles Dubost in 1951; he replaced an…

    Tweet Tweets with this article
    • Global CV Forum / The Past, Present, and Future of Complex Aortic Intervention | @JCoselli_MD @Texas_Heart @bcmhouston | #THIJournal https://t.co/LexPMny2RH https://t.co/ZnajndiqiA

  • Mashup Score: 0

    Innovation is not necessarily about the “next big thing” according to Mehta.1 Instead, innovation can occur by combining existing technologies, developing small ideas that compound, or evolving to address problems that have arisen from previous innovations that yielded unpredictable consequences. Innovation in the field of cardiovascular surgery is no different. As the field becomes progressively…

    Tweet Tweets with this article
    • Global CV Forum / Leveraging Innovation to Mitigate Risk During Heart Surgery | @MarcMoonMD @PujaKachroo @Texas_Heart @bcmhouston @WUSTLMed | #THIJournal https://t.co/WbLCfGneaX https://t.co/KUj4RwNRvw

  • Mashup Score: 0

    Mitral and tricuspid valvular disease have been managed surgically; however, multiple transcatheter technologies have diversified the therapeutic arsenal and expanded the number of patients eligible for treatment. These new technologies and active trials currently being performed at The Texas Heart Institute will be highlighted.Transcatheter edge-to-edge repair (TEER) with MitraClip (Abbott…

    Tweet Tweets with this article
    • Global CV Forum / Cutting-Edge Trials in Structural Heart Disease at The Texas Heart Institute | @YKherallah GV Silva @Texas_Heart @bcmhouston | #THIJournal https://t.co/EHxB1llQzQ https://t.co/jxbY2LPLO9